Search Results - "Monzó, Encarna"

Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia by Abrisqueta, Pau, Villamor, Neus, Terol, María José, González-Barca, Eva, González, Marcos, Ferrà, Christelle, Abella, Eugenia, Delgado, Julio, García-Marco, Jose A., González, Yolanda, Carbonell, Felix, Ferrer, Secundino, Monzó, Encarna, Jarque, Isidro, Muntañola, Ana, Constants, Mireia, Escoda, Lourdes, Calvo, Xavier, Bobillo, Sabela, Montoro, José Bruno, Montserrat, Emili, Bosch, Francesc

“…The effectiveness of rituximab maintenance therapy in the treatment of chronic lymphocytic leukemia has been investigated in a phase 2 clinical trial that…”
Get full text

Prognostic Factors and Treatment Results in Elderly Patients with Aggressive B-Cell Lymphoma: A Geltamo Observational Study by Pardal, Emilia, Diez-Baeza, Eva, González-Barca, Eva, Garcia-Cerecedo, Tomas, Monzo, Encarna, Sancho, Juan-Manuel, Moraleda, Jose Maria, Cordoba, Raul, De la Cruz, Fatima, Queizan, JA, Rodriguez-Salazar, Maria, Hernández-Rivas, JA, Navarro, Belen, Diez-Angulo, Rosana, Viguria, Maria Cruz, Vahi, Maria, Peñarrubia, Maria Jesús, Sanchez, Monica, Canales, Miguel, Gonzalez, Tomas, Alonso, Sara, Caballero, Maria Dolores, Martin, Alejandro

“…Introduction: Diffuse large B-cell lymphoma (DLBCL) is one of the most common malignant neoplasms in elderly patients, potentially curable when optimum…”
Get full text

Prognostic Impact of the MRD Status After Induction Treatment with Rituximab Plus Fludarabine, Cyclophosphamide and Mitoxantrone (R-FCM) in Patients with Chronic Lymphocytic Leukemia Receiving Rituximab Maintenance Therapy by Abrisqueta, Pau, Villamor, Neus, Terol, María José, González-Barca, Eva, González, Marcos, Ferrà, Christelle, Abella, Eugenia, Delgado, Julio, García-Marco, Jose Antonio, González, Yolanda, Carbonell, Felix, Ferrer, Secundino, Monzo, Encarna, Jarque, Isidro, Muntanola, Ana, Constants, Mireia, Escoda, Lourdes, Montserrat, Emili, Bosch, Francesc

“…Abstract 3930 Chemoimmunotherapy combination regimens achieve high rates of negative minimal residual disease responses in CLL, which has been correlated with…”
Get full text

Assessment of Minimal Residual Disease Levels in B-CLL After Front-Line Treatment with FC-R and Rituximab Maintenance by Garcia-Vela, Jose A., Lopez, Javier, Ferrer, Secundino, Giraldo, Pilar, González-Barca, Eva, Conde, Eulogio, González, Marcos, Guzman, Jose-Luis, De la Serna, Javier, Osma, Mar, Deben, Guillermo, Monzo, Encarna, De Paz, Raquel, Penalver, Francisco-Javier, Jarque, Isidro, Martinez, Rafael, Burgaleta, Carmen, de Oteiza, Jaime Perez, Andreu, M.Angeles, Carbonell, Felix, Garcia-Marco, Jose A

“…Abstract 4599 To prospectively analyze change over time in minimal residual disease (MRD) in a cohort of 84 untreated patients diagnosed with CD20+ B-CLL who…”
Get full text

Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) After Upfront Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM): Final Results of a Multicenter Phase II Trial On Behalf of the Spanish CLL Study Group (GELLC) by Bosch, Francesc, Abrisqueta, Pau, Villamor, Neus, Terol, María José, González-Barca, Eva, González, Marcos, Ferrà, Christelle, Abella, Eugenia, Delgado, Julio, Garcia-Marco, Jose A., Gonzalez, Yolanda, Carbonell, Felix, Ferrer, Secundino, Monzo, Encarna, Jarque, Isidro, Muntanola, Ana, Constants, Mireia, Escoda, Lourdes, Montserrat, Emili

“…Abstract▪293▪This icon denotes a clinically relevant abstract The effectiveness of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) followed…”
Get full text

Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) Sustains the Response Obtained After First-Line Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM) by Bosch, Francesc, Villamor, Neus, Abrisqueta, Pau, Terol, María José, González-Barca, Eva, González, Marcos, Ferrà, Christelle, Abella, Eugenia, Delgado, Julio, Garcia-Marco, Jose A, Gonzalez, Yolanda, Carbonell, Felix, Ferrer, Secundino, Monzo, Encarna, Jarque, Isidro, Muntanola, Ana, Constants, Mireia, Escoda, Lourdes, Montserrat, Emili

“…Abstract 1382 The effectiveness of rituximab maintenance in the treatment of CLL has been investigated in a phase II clinical trial that includes two treatment…”
Get full text

Rituximab Maintenance Treatment After Combined Fludarabine, Cyclophosphamide and Rituximab In Previously Untreated Patients with Progressive B-Cell Chronic Lymphocytic Leukemia (CLL): Interim Analysis of An Ongoing Phase II Multicenter Trial On Behalf of the Spanish CLL Study Group (GELLC) by Garcia-Marco, Jose A, Lopez-Jimenez, Javier, Ferrer, Secundino, Giraldo, Pilar, González-Barca, Eva, Navarro, Belen, Conde, Eulogio, González, Marcos, Guzman, Jose L., Perez, Ernesto, De la Serna, Javier, Osma, Mar, Deben, Guillermo, Monzo, Encarna, de Paz, Raquel, Ruiz, M. Angeles, Penalver, Francisco-Javier, Jarque, Isidro, Bañas, Helena, Fernandez, M. Carmen, Martinez, Rafael, Burgaleta, Carmen, de Oteiza, Jaime Perez, Andreu, M.Angeles, Carral, Ana, Fuentes, Inmaculada, Donato, Eva, Leon, Paola, Carbonell, Felix, Garcia-Vela, Jose A.

“…Abstract 2448 Combination of Rituximab (R) with fludarabine (F) and cyclophosphamide (C) as first line treatment of B-CLL, results in a high complete response…”
Get full text

5.40 Rituximab Maintenance in Patients with Chronic Lymphocytic Leukemia after First-Line Treatment with Rituximab plus Fludarabine, Cyclophosphamide, and Mitoxantrone: Final Results of a Multicenter Phase II Trial on Behalf of the Spanish CLL Study Group (GELLC) by Bosch, Francesc, Abrisqueta, Pau, Villamor, Neus, Terol, María José, González-Barca, Eva, González, Marcos, Ferrà, Christelle, Abella, Eugenia, Delgado, Julio, Garcia-Marco, Jose A, Gonzalez, Yolanda, Carbonell, Felix, Ferrer, Secundino, Monzo, Encarna, Jarque, Isidro, Muntanola, Ana, Constants, Mireia, Escoda, Lourdes, Montserrat, Emili

Get full text

Follicular mucinosis and Hodgkin's disease by Ramon, D, Jorda, E, Molina, I, Galan, A, Torres, V, Alcacer, J, Monzo, E

Get more information